Journées Francophones d'Hépato-Gastroentérologie Et d'Oncologie Digestive (JFHOD) 2019
DOI: 10.1055/s-0039-1680924
|View full text |Cite
|
Sign up to set email alerts
|

Résultats de la prise en charge endoscopique de l'ulcère gastroduodénal hémorragique: une série de 125 patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…For instance, the risk of developing upper and lower gastroduodenal bleeding is high in patients treated with ASA, in the prevention or in the treatment of ischemic cardiovascular diseases [16, 17]. Although the treatment of HP infections has improved significantly in recent years due to the development of the antibiotic pharmaceutical industry, the prevalence of peptic ulcer morbidity has not decreased accordingly and mortality from such a pathology (2.5% to 5.8%) still remains a public health concern [18]. Conventional treatments for peptic ulcers are based on one hand on the reduction of factors that induce gastric mucosal damage, such as proton pump inhibitors (IPPs), anticholinergics, histaminic H 2 -receptor antagonists, and antacids, and on the other hand on the improvement of the protective mucosal layer by mucus production or by synthetic mucus mimetic drugs [6, 19, 20].…”
Section: Introductionmentioning
confidence: 99%
“…For instance, the risk of developing upper and lower gastroduodenal bleeding is high in patients treated with ASA, in the prevention or in the treatment of ischemic cardiovascular diseases [16, 17]. Although the treatment of HP infections has improved significantly in recent years due to the development of the antibiotic pharmaceutical industry, the prevalence of peptic ulcer morbidity has not decreased accordingly and mortality from such a pathology (2.5% to 5.8%) still remains a public health concern [18]. Conventional treatments for peptic ulcers are based on one hand on the reduction of factors that induce gastric mucosal damage, such as proton pump inhibitors (IPPs), anticholinergics, histaminic H 2 -receptor antagonists, and antacids, and on the other hand on the improvement of the protective mucosal layer by mucus production or by synthetic mucus mimetic drugs [6, 19, 20].…”
Section: Introductionmentioning
confidence: 99%